Written question asked by Ian Gibson (Labour) on Tuesday, 31 March 2009, in the House of Commons. It was due for an answer on Thursday, 2 April 2009. It was answered by Baroness Primarolo (Labour) on Tuesday, 21 April 2009 on behalf of the Department of Health.
Cancer: Drugs
- Question
- To ask the Secretary of State for Health when the National Institute for Health and Clinical Excellence will produce its guidance on the use of (a) bevacizumab, (b) sorafenib, (c) sunitinib (second-line) and (d) temsirolimus for the treatment of advanced and metastatic renal cell carcinoma in the NHS.
- Answer
-
The National Institute for Health and Clinical Excellence currently expects to issue final guidance to the national health service on bevacizumab, sorafenib and temsirolimus for the first line treatment and sorafenib and sunitinib for the second-line treatment of advanced and/or metastatic renal cell carcinoma in June 2009.
Secondary information
- Type
- Written question
- Reference
- 491 c574W; 268705
- Session
- 2008-09
- Subjects
- Health services Drugs Kidney cancer
- Link
- View this Written question on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2025-02-17 10:56:57 +0000
- URI
- http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_1409994
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_1409994
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_1409994